Vaxcyte, Inc.
PCVX
Rang in aandelen
#2112
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Aandeelprijs
$63.40
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$9.72B
Verandering (1 dag)
-2.87%
Verandering (1 jaar)
49.56%
Land
US
Handel Vaxcyte, Inc. (PCVX)
Categorie
Healthcare
EPS voor Vaxcyte, Inc. (PCVX)
EPS per June 2026 TTM: $-7.64
Volgens de laatste financiële rapporten en de aandelenkoers van Vaxcyte, Inc. is de huidige EPS van het bedrijf (TTM) $-7.64. Eind 2023 had het bedrijf een EPS van $-4.14, een stijging ten opzichte van de EPS van 2022 die $-3.44 bedroeg.
EPS-geschiedenis van Vaxcyte, Inc. van 2017 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-7.64 | 101.05% |
| 2024 | $-3.80 | -8.21% |
| 2023 | $-4.14 | 20.35% |
| 2022 | $-3.44 | 78.24% |
| 2021 | $-1.93 | -35.02% |
| 2020 | $-2.97 | -78.94% |
| 2019 | $-14.10 | 73.65% |
| 2018 | $-8.12 | 67.77% |
| 2017 | $-4.84 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -326.70% |
US
|
|
| $-7.98 | 4.45% |
US
|
|
| $-5.29 | -30.76% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -463.09% |
NL
|
